You are here

Article Text

Article menu
Download PDFPDF
Heart failure and cardiomyopathies
Original research
Phenotyping of acute decompensated heart failure with preserved ejection fraction
  1. Yohei Sotomi1,
  2. Shungo Hikoso1,
  3. Sho Komukai2,
  4. Taiki Sato1,
  5. Bolrathanak Oeun1,
  6. Tetsuhisa Kitamura3,
  7. Akito Nakagawa4,5,
  8. Daisaku Nakatani1,
  9. Hiroya Mizuno1,
  10. Katsuki Okada1,6,
  11. Tomoharu Dohi1,
  12. Akihiro Sunaga1,
  13. Hirota Kida1,
  14. Masahiro Seo7,
  15. Masamichi Yano8,
  16. Takaharu Hayashi9,
  17. Yusuke Nakagawa10,
  18. Shunsuke Tamaki11,
  19. Tomohito Ohtani1,
  20. Yoshio Yasumura4,
  21. Takahisa Yamada7,
  22. Yasushi Sakata1
  23. on behalf of the OCVC-Heart Failure Investigator
  1. 1 Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
  2. 2 Division of Biomedical Statistics, Department of Integrated Medicine, Osaka University Graduate School of Medicine, Osaka, Osaka, Japan
  3. 3 Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
  4. 4 Division of Cardiology, Amagasaki Chuo Hospital, Hyogo, Japan
  5. 5 Department of Medical Informatics, Osaka University Graduate School of Medicine, Osaka, Japan
  6. 6 Department of Transformative System for Medical Information, Osaka University Graduate School of Medicine, Osaka, Japan
  7. 7 Division of Cardiology, Osaka General Medical Center, Osaka, Japan
  8. 8 Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan
  9. 9 Cardiovascular Division, Osaka Police Hospital, Osaka, Japan
  10. 10 Division of Cardiology, Kawanishi City Hospital, Hyogo, Japan
  11. 11 Department of Cardiology, Rinku General Medical Center, Osaka, Japan
  1. Correspondence to Dr Shungo Hikoso, Department of Cardiology, Osaka University Graduate School of Medicine, Suita, Japan; hikoso{at}cardiology.med.osaka-u.ac.jp

Abstract

Objective The pathophysiological heterogeneity of heart failure with preserved ejection fraction (HFpEF) makes the conventional ‘one-size-fits-all’ treatment approach difficult. We aimed to develop a stratification methodology to identify distinct subphenotypes of acute HFpEF using the latent class analysis.

Methods We established a prospective, multicentre registry of acute decompensated HFpEF. Primary candidates for latent class analysis were patient data on hospital admission (160 features). The patient subset was categorised based on enrolment period into a derivation cohort (2016–2018; n=623) and a validation cohort (2019–2020; n=472). After excluding features with significant missingness and high degree of correlation, 83 features were finally included in the analysis.

Results The analysis subclassified patients (derivation cohort) into 4 groups: group 1 (n=215, 34.5%), characterised by arrythmia triggering (especially atrial fibrillation) and a lower comorbidity burden; group 2 (n=77, 12.4%), with substantially elevated blood pressure and worse classical HFpEF echocardiographic features; group 3 (n=149, 23.9%), with the highest level of GGT and total bilirubin and frequent previous hospitalisation for HF and group 4 (n=182, 29.2%), with infection-triggered HF hospitalisation, high C reactive protein and worse nutritional status. The primary end point—a composite of all-cause death and HF readmission—significantly differed between the groups (log-rank p<0.001). These findings were consistent in the validation cohort.

Conclusions This study indicated the feasibility of clinical application of the latent class analysis in a highly heterogeneous cohort of patients with acute HFpEF. Patients can be divided into 4 phenotypes with distinct patient characteristics and clinical outcomes.

Trial registration number UMIN000021831.

  • heart failure with preserved ejection fraction

Data availability statement

No data are available. Our study data will not be made available to other researchers for purposes of reproducing the results because of institutional review board restrictions.

https://doi.org/10.1136/heartjnl-2021-320270

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    No data are available. Our study data will not be made available to other researchers for purposes of reproducing the results because of institutional review board restrictions.

    View Full Text

    Footnotes

    • Contributors Concept and design: YSo, SH, SK, TS, BO, TK, AN and YSa. Data analysis and statistical analysis: YSo, SK and TS. Manuscript draft: YSo, SH, SK, TS, BO, TK, AN and YSa. Critical revision, editing and approval of the final manuscript: all authors. Guarantor: YSo, SH, and YSa.

    • Funding This work was funded by Roche Diagnostics K.K. and Fuji Film Toyama Chemical Co. Ltd.

    • Competing interests YSo has received personal fees from Daiichi-Sankyo, Bayer, Boehringer Ingelheim and Bristol-Myers Squibb. SH has received grants from Roche Diagnostics, FUJIFILM Toyama Chemical, Actelion Pharmaceuticals; and personal fees from Daiichi-Sankyo, Astellas Pharma, Bayer, Pfizer Pharmaceuticals, Boehringer Ingelheim Japan, Kowa Company and Ono Pharmaceutical. DN has received personal fees from Roche Diagnostics. HM is an endowed chair lecturer supported by Asahi Intecc, Terumo Corporation, Nipro Corporation and Shimadzu Corporation, and has received personal fees from Medtronic Japan, Japan Tobacco, Pfizer Japan, Bayer Yakuhin, Japan Lifeline, Abbott Japan, Nippon Boehringer Ingelheim, Toa Eiyo, Daiichi-Sankyo and Kowa. KO has received personal fees from Bayer. YSa has received personal fees from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, AstraZeneca and Actelion Pharmaceuticals, and grants from Roche Diagnostic, FUJIFILM Toyama Chemical, Bristol-Myers Squibb, Biosense Webster, Abbott Medical Japan, Otsuka Pharmaceutical, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, Astellas Pharma, Kowa Company, Boehringer Ingelheim Japan and Biotronik.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.